<DOC>
	<DOCNO>NCT00017290</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Vaccines may make body build immune response kill cancer cell . It yet know regimen chemotherapy combine vaccine therapy effective non-Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial determine effectiveness combination chemotherapy follow vaccine therapy plus sargramostim treating patient stage III stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim Treating Patients With Stage III Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare time tumor progression patient stage III IV follicular B-cell non-Hodgkin 's lymphoma treat cyclophosphamide , prednisone , vincristine follow immunotherapy keyhole limpet hemocyanin without autologous tumor-derived immunoglobulin idiotype adjuvant sargramostim ( GM-CSF ) . - Compare efficacy immunotherapy regimens term convert patient partial response unconfirmed complete response clinical complete response . - Compare safety toxic effect immunotherapy regimens patient population . - Compare time treatment failure survival patient treat regimen . - Correlate induction idiotype-specific immune response clinical benefit achieve molecular remission patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients receive cyclophosphamide IV 30-40 minute vincristine IV day 1 . Patients also receive oral prednisone day 1-5 . Treatment repeat every 21 day 8 course . At 6 month completion chemotherapy , patient maintain partial response ( PR ) , complete response ( CR ) , unconfirmed complete response ( CRU ) receive immunotherapy . Patients stratify accord participate center baseline disease status ( PR v CR/CRU ) . Patients randomize one two treatment arm . - Arm I : Patients receive autologous tumor-derived immunoglobulin idiotype conjugate keyhole limpet hemocyanin ( KLH ) subcutaneously ( SC ) day 1 adjuvant sargramostim ( GM-CSF ) SC day 1-4 week 0 , 4 , 8 , 12 , 16 , 20 , 24 . - Arm II : Patients receive KLH alone SC day 1 GM-CSF SC day 1-4 week 0 , 4 , 8 , 12 , 16 , 20 , 24 . Quality life assess prior first immunization , 2-8 week completion immunization , every 6 month 30 month . Patients follow every 3 month 1 year every 6 month thereafter . Patients also enroll long-term follow-up study additional 5 year . PROJECTED ACCRUAL : A total 360 patient ( 240 arm I 120 arm II ) accrue 480 patient biopsied study within 15-18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV follicular Bcell nonHodgkin 's lymphoma At least 1 bidimensionally measurable lesion radiography , addition lesion remove biopsy No clinical evidence CNS involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Hepatitis B surface antigen negative Hepatitis C antibody negative Renal : Creatinine le 1.5 time ULN Other : No malignancy within past 5 year except adequately treat basal squamous cell skin cancer carcinoma situ cervix No history autoimmune disease HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior antibody therapy lymphoma Chemotherapy : No prior cytotoxic therapy lymphoma Endocrine therapy : No prior corticosteroid lymphoma At least 12 month since prior corticosteroid immunosuppressant condition Prior transient corticosteroid ( prior CT imaging ) optical solution allow Radiotherapy : Prior radiotherapy lymphoma ( 2 site limited disease ) allow Surgery : See Disease Characteristics Other : No concurrent participation therapeutic clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2002</verification_date>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>